drugset / Trial / NCT07059611
Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
Phase 2
Not yet recruiting
34 enrolled
Abramson Cancer Center at Penn Medicine
Replimune, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The research study is being conducted to study whether performing injections of a new treatment, called RP2, directly into stomach and esophagus tumors along with standard chemotherapy (called FLOT) is safe and whether it does a better job of killing cancer before surgery compared to chemotherapy alone.
Timeline
- Start
- 2026-09-01
- Primary completion
- 2027-11-01
- Completion
- 2029-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RP2 | Other / unclassified | 10 ml | Other |
| Background | Docetaxel | Small molecule | 50 mg/m2 | Intravenous |
| Background | Leucovorin | Small molecule | 200 mg/m2 | Intravenous |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Background | Pegfilgrastim | Protein / enzyme biologic | — | — |
| Background | filgrastim | Protein / enzyme biologic | — | — |
| Background | fluorouracil | Small molecule | 2600 mg/m2 | Intravenous |